Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài:Evaluation of the Patient Acceptable Symptom State in a pooled analysis of two multicentre, randomised, double-blind, placebo-controlled studies evaluating lumiracoxib and celecoxib in patients with osteoarthritis. | Available online http content 9 1 R11 Research article Evaluation of the Patient Acceptable Symptom State in a pooled analysis of two multicentre randomised double-blind placebo-controlled studies evaluating lumiracoxib and celecoxib in patients with osteoarthritis Maxime Dougados1 Alan Moore2 Shaohua Yu3 and Xavier Gitton4 Open Access Department of Rheumatology Hôpital Cochin 27 Rue du Faubourg Saint Jacques 75014 Paris France 2Biostatistics Novartis Pharma AG Lichtstrasse 35 CH-4056 Basel Switzerland 3Biostatistics Novartis Pharmaceuticals Corporation One Health Plaza East Hanover NJ 07936 USA 4Clinical Development Medical Affairs Novartis Pharma AG Lichtstrasse 35 CH-4056 Basel Switzerland Corresponding author Maxime Dougados Received 11 Sep 2006 Revisions requested 6 Nov 2006 Revisions received 3 Jan 2007 Accepted 31 Jan 2007 Published 31 Jan 2007 Arthritis Research Therapy 2007 9 R11 doi ar2118 This article is online at http content 9 1 R11 2007 Dougados et al. licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Patient Acceptable Symptom State PASS is an absolute threshold proposed for symptomatic variables in osteoarthritis OA to determine the point beyond which patients consider themselves well and as such are satisfied with treatment. Two large previously reported studies of knee OA have shown that both lumiracoxib and celecoxib were superior to placebo in terms of conventional outcome measures. To assess the clinical relevance of these results from the patient s perspective the same data pooled from these two studies were analysed with respect to the PASS. In total 3 235 patients were included in two multicentre randomised .
